What is ABUS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.84B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ABUS?

P/E (TTM) is 5.46 and 52-week range is $3.50 to $5.45 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ABUS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ABUS?

The company profile lists revenue (TTM) near $182M, net income (TTM) near $153M, EPS (TTM) near $0.78 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Arbutus Biopharma Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Warminster, British Columbia, CA, 197.5M shares outstanding, ISIN CA03879J1003 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Arbutus Biopharma Corp

$ABUS

Health Care · Biotechnology

IR Run Scenarios

$4.22

+0.96%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. The company is headquartered in Warminster, British Columbia and currently employs 19 full-time employees. The company went IPO on 2010-11-13. The firm is developing imdusiran (AB-729), its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). Its HBV product pipeline includes Imdusiran and AB-101. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for. PD-L1 inhibitors complement its pipeline of agents and could potentially be a part of a combination therapy for the treatment of HBV by reawakening the immune system.

Employees

Website

www.arbutusbio.com/

IPO

2010-11-13

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)